Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXN Alexion Pharmaceuticals	$182.50	$182.82	$99.91 ▼ $187.45	$40.34B	1.25	3.31 million shs	10 shs
BAYRY Bayer Aktiengesellschaft	$7.54 -4.2%	$7.06	$4.79 ▼ $8.58	$30.93B	0.85	545,846 shs	377,279 shs
REGN Regeneron Pharmaceuticals	$525.00 +0.8%	$554.18	$476.49 ▼ $1,211.20	$56.25B	0.31	900,032 shs	1.01 million shs
TAK Takeda Pharmaceutical	$15.46 +2.4%	$14.83	$12.80 ▼ $15.48	$48.05B	0.23	1.97 million shs	3.12 million shs
VRTX Vertex Pharmaceuticals	$445.20 +0.9%	$454.50	$377.85 ▼ $519.88	$113.32B	0.42	1.42 million shs	1.11 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXN Alexion Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
BAYRY Bayer Aktiengesellschaft	0.00%	+2.47%	+11.47%	+30.73%	+11.79%
REGN Regeneron Pharmaceuticals	0.00%	+2.21%	+5.63%	-17.85%	-50.43%
TAK Takeda Pharmaceutical	0.00%	+2.44%	+0.63%	+1.55%	+16.73%
VRTX Vertex Pharmaceuticals	0.00%	+0.10%	-0.39%	-8.98%	-5.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALXN Alexion Pharmaceuticals	1.371 of 5 stars	0.0	0.0	0.0	3.8	0.6	1.7	1.9
BAYRY Bayer Aktiengesellschaft	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	4.9274 of 5 stars	4.4	5.0	1.7	2.3	2.7	1.7	1.9
TAK Takeda Pharmaceutical	1.2015 of 5 stars	0.0	3.0	2.5	0.0	2.5	0.0	0.6
VRTX Vertex Pharmaceuticals	4.6885 of 5 stars	3.3	5.0	0.0	3.3	3.3	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXN Alexion Pharmaceuticals	0.00	N/A	N/A	N/A
BAYRY Bayer Aktiengesellschaft	3.25	Buy	N/A	N/A
REGN Regeneron Pharmaceuticals	2.80	Moderate Buy	$813.57	54.96% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A
VRTX Vertex Pharmaceuticals	2.54	Moderate Buy	$511.62	14.92% Upside

Current Analyst Ratings Breakdown

Latest VRTX, TAK, BAYRY, REGN, and ALXN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	REGN Regeneron Pharmaceuticals	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/23/2025	VRTX Vertex Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$550.00
6/20/2025	VRTX Vertex Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$464.00 ➝ $460.00
6/17/2025	VRTX Vertex Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Perform ➝ Sector Perform	$423.00 ➝ $420.00
6/11/2025	BAYRY Bayer Aktiengesellschaft	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/11/2025	BAYRY Bayer Aktiengesellschaft	Kepler Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
6/9/2025	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$950.00 ➝ $800.00
6/5/2025	BAYRY Bayer Aktiengesellschaft	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/5/2025	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$633.00 ➝ $560.00
6/2/2025	REGN Regeneron Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$700.00 ➝ $650.00
6/2/2025	REGN Regeneron Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$800.00 ➝ $600.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXN Alexion Pharmaceuticals	$6.07B	6.65	$22.81 per share	8.00	$53.24 per share	3.43
BAYRY Bayer Aktiengesellschaft	$50.44B	0.59	$3.63 per share	2.08	$8.82 per share	0.85
REGN Regeneron Pharmaceuticals	$14.20B	3.99	$46.05 per share	11.40	$268.50 per share	1.96
TAK Takeda Pharmaceutical	$30.09B	1.64	$3.25 per share	4.75	$14.39 per share	1.07
VRTX Vertex Pharmaceuticals	$11.02B	10.37	N/A	N/A	$63.72 per share	6.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXN Alexion Pharmaceuticals	$603.40M	$11.60	59.64	13.15	0.93	10.89%	23.43%	15.06%	N/A
BAYRY Bayer Aktiengesellschaft	-$2.76B	-$0.92	N/A	6.61	N/A	-7.26%	13.94%	4.09%	8/5/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	13.37	13.81	1.91	31.94%	15.27%	11.93%	7/30/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.22	70.28	9.37	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$3.92	N/A	25.43	N/A	-8.91%	-3.36%	-2.42%	7/30/2025 (Estimated)

Latest VRTX, TAK, BAYRY, REGN, and ALXN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	BAYRY Bayer Aktiengesellschaft	$0.63	$0.65	+$0.02	$0.35	$13.39 billion	$15.27 billion
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
5/5/2025	Q1 2025	VRTX Vertex Pharmaceuticals	$4.29	$4.06	-$0.23	$2.49	$2.85 billion	$2.77 billion
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	$8.22	-$0.61	$7.27	$3.40 billion	$3.03 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXN Alexion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BAYRY Bayer Aktiengesellschaft	$0.02	0.27%	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.67%	N/A	8.96%	N/A
TAK Takeda Pharmaceutical	$0.55	3.56%	N/A	250.00%	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest VRTX, TAK, BAYRY, REGN, and ALXN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025
4/22/2025	BAYRY Bayer Aktiengesellschaft		$0.0224	0.38%	4/29/2025	4/30/2025	5/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXN Alexion Pharmaceuticals	0.19	4.52	3.96
BAYRY Bayer Aktiengesellschaft	1.07	1.25	0.79
REGN Regeneron Pharmaceuticals	0.09	4.93	4.03
TAK Takeda Pharmaceutical	0.57	1.01	0.52
VRTX Vertex Pharmaceuticals	0.01	2.65	2.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXN Alexion Pharmaceuticals	82.94%
BAYRY Bayer Aktiengesellschaft	N/A
REGN Regeneron Pharmaceuticals	83.31%
TAK Takeda Pharmaceutical	9.17%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
ALXN Alexion Pharmaceuticals	4.03%
BAYRY Bayer Aktiengesellschaft	N/A
REGN Regeneron Pharmaceuticals	7.02%
TAK Takeda Pharmaceutical	0.04%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXN Alexion Pharmaceuticals	3,837	221.02 million	N/A	Optionable
BAYRY Bayer Aktiengesellschaft	92,815	3.93 billion	N/A	Not Optionable
REGN Regeneron Pharmaceuticals	15,106	107.96 million	100.39 million	Optionable
TAK Takeda Pharmaceutical	49,281	3.18 billion	3.18 billion	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.80 million	256.28 million	Optionable

VRTX, TAK, BAYRY, REGN, and ALXN Headlines

Recent News About These Companies

VRTX Vertex Pharmaceuticals Incorporated - Seeking Alpha

5 hours ago | seekingalpha.com

Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?

June 30 at 9:31 AM | zacks.com

New York State Teachers Retirement System Trims Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 30 at 6:41 AM | marketbeat.com

Amalgamated Bank Increases Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 30 at 6:32 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Allspring Global Investments Holdings LLC

June 30 at 4:47 AM | marketbeat.com

H.C. Wainwright Reaffirms Vertex Buy Rating After ADA Conference Results

June 29 at 2:18 PM | msn.com

Goodman Advisory Group LLC Makes New Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 29 at 6:41 AM | marketbeat.com

TBH Global Asset Management LLC Invests $297,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 29 at 6:24 AM | marketbeat.com

Perpetual Ltd Makes New Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 29 at 4:30 AM | marketbeat.com

GAMMA Investing LLC Raises Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 29 at 3:03 AM | marketbeat.com

Little House Capital LLC Purchases 1,573 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 28 at 8:17 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Sumitomo Mitsui Trust Group Inc.

June 28 at 8:17 AM | marketbeat.com

Heirloom Wealth Management Grows Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 28 at 7:12 AM | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Has $69.55 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 28 at 5:43 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Sequoia Financial Advisors LLC

June 28 at 4:11 AM | marketbeat.com

Golden State Wealth Management LLC Acquires 567 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 28 at 4:04 AM | marketbeat.com

Moran Wealth Management LLC Sells 29,300 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 28 at 3:49 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives $513.14 Consensus Price Target from Brokerages

June 28 at 3:04 AM | americanbankingnews.com

Equities Analysts Offer Predictions for VRTX Q3 Earnings

June 28 at 2:08 AM | americanbankingnews.com

Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug

June 27 at 10:19 AM | insidermonkey.com

Philip James Wealth Mangement LLC Purchases New Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 27 at 8:17 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Applied Digital: Now the High-Stakes Race to Build Begins
By Jeffrey Neal Johnson | June 17, 2025
View Applied Digital: Now the High-Stakes Race to Build Begins
Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
By Jeffrey Neal Johnson | June 4, 2025
View Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
Lululemon, UNH, Enphase: Bad News, Good Opportunity?
By Thomas Hughes | June 17, 2025
View Lululemon, UNH, Enphase: Bad News, Good Opportunity?
Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names
By Leo Miller | June 10, 2025
View Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names
Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?
By Nathan Reiff | June 20, 2025
View Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?

VRTX, TAK, BAYRY, REGN, and ALXN Company Descriptions

Alexion Pharmaceuticals NASDAQ:ALXN

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Bayer Aktiengesellschaft OTCMKTS:BAYRY

$7.54 -0.33 (-4.19%)

As of 04:00 PM Eastern

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Regeneron Pharmaceuticals NASDAQ:REGN

$525.00 +4.00 (+0.77%)

As of 04:00 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Takeda Pharmaceutical NYSE:TAK

$15.46 +0.36 (+2.38%)

As of 03:58 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Vertex Pharmaceuticals NASDAQ:VRTX

$445.20 +3.90 (+0.88%)

As of 04:00 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRTX, TAK, BAYRY, REGN, and ALXN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRTX, TAK, BAYRY, REGN, and ALXN Earnings

Compare Dividends

Latest VRTX, TAK, BAYRY, REGN, and ALXN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRTX, TAK, BAYRY, REGN, and ALXN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VRTX, TAK, BAYRY, REGN, and ALXN Company Descriptions

Alexion Pharmaceuticals NASDAQ:ALXN

Bayer Aktiengesellschaft OTCMKTS:BAYRY

Regeneron Pharmaceuticals NASDAQ:REGN

Takeda Pharmaceutical NYSE:TAK

Vertex Pharmaceuticals NASDAQ:VRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools